{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+care+alone&page=72",
    "query": {
      "intervention": "Standard care alone",
      "page": 72
    },
    "page_size": 10
  },
  "pagination": {
    "page": 72,
    "page_size": 10,
    "total_count": 2854,
    "total_pages": 286,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+care+alone&page=73&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+care+alone&page=71&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T16:21:11.578Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02343263",
      "title": "Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain, Postoperative",
        "Postoperative Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Fibrin Sealant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Year to 12 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-03",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-08-10",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343263"
    },
    {
      "nct_id": "NCT07654907",
      "title": "Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "EpiFaith™ Syringe",
          "type": "DEVICE"
        },
        {
          "name": "Conventional Loss-of-Resistance Syringe",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Flat Medical Co., Ltd",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-05-28",
      "completion_date": "2026-12-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Temecula, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Temecula",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07654907"
    },
    {
      "nct_id": "NCT05610852",
      "title": "Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Transvesical Single Port Robotic Partial Prostatectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "High-intensity focused ultrasound (HIFU)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 276,
      "start_date": "2024-01-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05610852"
    },
    {
      "nct_id": "NCT05284747",
      "title": "EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Disease",
        "Myocardial Infarction",
        "Stroke",
        "Coronary Revascularization"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Routine Lipid Management",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 6019,
      "start_date": "2022-10-26",
      "completion_date": "2027-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05284747"
    },
    {
      "nct_id": "NCT04157348",
      "title": "Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Granulomatous Vasculitis"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Benralizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 140,
      "start_date": "2019-10-29",
      "completion_date": "2026-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157348"
    },
    {
      "nct_id": "NCT03977467",
      "title": "Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-08-30",
      "completion_date": "2024-08-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 7,
      "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03977467"
    },
    {
      "nct_id": "NCT05500092",
      "title": "An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Resectable Stage IIA to IIIB Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "(8gy x 3)",
          "type": "RADIATION"
        },
        {
          "name": "Platinum Doublet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-01-25",
      "completion_date": "2030-05",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "White Plains",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500092"
    },
    {
      "nct_id": "NCT05934851",
      "title": "A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vulvar Neoplasm",
        "Dysplasia Vulvar"
      ],
      "interventions": [
        {
          "name": "Frozen-Section Directed Excision",
          "type": "PROCEDURE"
        },
        {
          "name": "Wide Local Excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2023-11-07",
      "completion_date": "2026-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05934851"
    },
    {
      "nct_id": "NCT02908477",
      "title": "Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Oropharynx Cancer"
      ],
      "interventions": [
        {
          "name": "Adjuvant Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2016-10-03",
      "completion_date": "2024-11-15",
      "has_results": true,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02908477"
    },
    {
      "nct_id": "NCT07552181",
      "title": "Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer",
        "TNBC",
        "Early Stage Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Live biotherapeutic product: MO-03 1 capsule PO BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yuan Yuan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-09",
      "completion_date": "2035-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-11-19T16:21:11.578Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Tarzana, California • Torrance, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07552181"
    }
  ]
}